Capstone Partners served as exclusive financial advisor to Neoteryx, LLC in connection with its sale to Trajan Group Holdings Limited (Australian Stock Exchange: TRJ).
Neoteryx, based in Southern California, is a global leader in blood microsampling with operations in the U.S. and Europe.
The Company’s Mitra® devices and proprietary VAMS® technology facilitate more convenient and accurate remote specimen collection, providing better scientific and medical insights.
Headquartered in Melbourne, Australia, Trajan is a global developer and manufacturer of analytical and life sciences products and devices used in the analysis of biological, food, water and other environmental samples.
The transaction further enhances Trajan’s vision to accelerate adoption of remote sampling technologies, expand consumer engagement and facilitate personalized data-based healthcare decisions.
At Neoteryx we developed innovative technology to transform specimen collection, and our goal was to achieve global commercial scale through a strategic transaction. [Capstone Partners] brought deep industry expertise and relationships to this assignment, and a sharp focus on achieving our objectives. Our partnership with Trajan is an exciting outcome for the Neoteryx team and our customers as we together leverage micro-sampling to create advanced healthcare solutions.
